Traditional Chinese medicine drug Tongxinlo reduces cardiovascular risk by 30% in heart attack survivors. The research was published in the journal JAMA.
In 1996, the traditional Chinese medicine drug Tongxinluo was approved in China for the treatment of attacks of pressing chest pain (angina) and the rehabilitation of patients after stroke and heart attack.
In a new study, researchers from the University of Texas evaluated the drug’s effectiveness using data from 3,777 patients from 124 clinical sites in China. Between 2019 and 2020, they all suffered acute myocardial infarction and a blood clot was removed from the artery that carries blood to the heart. Over the next 12 months, in addition to standard treatment (beta blockers and aspirin), half of them were prescribed Tongxinlo, while the other was given a similar-tasting placebo.
Heart attacks, strokes and other heart problems were 30 percent less common in patients taking the Chinese medicine than in the placebo group. The authors of the study believe that such a significant difference proves the effectiveness of Tongxinlo in preventing heart problems after a heart attack.
Previous scientists to create A factor that will not improve heart health without vitamin D.